GLOBAL AMR R&D HUB: Work Plan 2022-2024

The COVID-19 pandemic has spurred a shift in global health priorities and highlighted the need to strengthen health security and preparedness, with innovative research alongside co-ordinated global responses pivotal to achieving this goal. Leveraging this momentum and lessons learned, it is time to effectively tackle AMR, recognising that it continues to set the global health community back from achieving universal health coverage and the Sustainable Development Goals (SDGs).

Our approach is targeted and iterative, aligning with and leveraging ongoing developments in the global health and policy landscape for impact. Leveraging its truly global network, accumulating knowledge foundation and unique resources, including the [Dynamic Dashboard](#), the Hub's Work Plan for 2022-2024 focuses on the long-term implementation of its mandate with a One Health lens.

A focus will be placed on strengthening activities in the following areas:

- **Knowledge generation – evidence base & thought leadership**

  - providing the evidence base for helping countries identify gaps, opportunities and potential for collaboration in AMR R&D
  - driving thought leadership through knowledge synthesis and interpretation of data

- **Strategic collaborations – co-creating solutions**

  - promoting increased collaboration & coordination between Hub Board members, including sharing of best practices and challenges in the fields of AMR R&D and market incentives
  - promoting and strengthening linkages between and with key AMR actors to amplify aligned messages and deliver outputs

- **Raising awareness – pro-active not reactive**

  - at the highest political levels to guide sustainable and focused investment in AMR R&D from both the public and private sector

Key thematic areas of immediate interest are:

- One Health; Market incentives (includes market entry support, clinical trials, stewardship, access, regulatory issues, and financial models); Diagnostics

To amplify impact, activities will focus on **increasing opportunities for communication, sharing lessons learned and collaboration between Hub Board Members that lead to action**. In addition, communication efforts will be focused around key fora:

- G7 - Italy 2024; Canada 2024
- G20 - Brazil 2024;
- European Council Presidency - Spain 2023; Belgium 2024
- Global Leaders Group on AMR;
- Quadripartite for One Health;

o   Independent Panel on Evidence for Action against AMR
o   AMR Multi-Partner Trust Fund;
o   AMR Multi-Stakeholder Partnership Platform and
o   Relevant national and regional governments.

The <u>Work Plan</u> is divided across the Hub's three strategic pillars:

o   Independent Panel on Evidence for Action against AMR
o   AMR Multi-Partner Trust Fund;
o   AMR Multi-Stakeholder Partnership Platform and

Pillar 1: Guide and support evidence-based decision making

Focus	Knowledge generation – evidence base & thought leadership	
Outcome	Increased, focused and sustainable funding for AMR R&D and market incentives for priority products addressing AMR	
Key Performance Indicators	o Number of Hub outputs that identify gaps and opportunities in AMR R&D o Number of Hub outputs guiding decision making on market incentives for antibacterial development o Number of countries and institutions using Hub outputs as part of their decision-making toolkit o Number of external reports/analyses using Hub data o Number of Dynamic Dashboard users per month	
Activities	**Dynamic Dashboard Analysis Reports** o **B i - a n n u a l R e p o r t** s ynthesis of information in the Dynamic Dashboard - high level overview of each Gallery. Up to 2 case studies going more in-depth into specific topics and emerging trends over time. o **Dynamic Dashboard Fact Sheets** - interim data on product related AMR R&D funding o **Report on usage of the Dynamic Dashboard** by countries and relevant organisations. o To include roadmap of how to improve uptake and translation of the information from the Dashboard	• Bi-annual Report – Nov 2023 • Fact Sheets: Started Dec 2022 (then regular updates) • DD Evaluation Report - Dec 2023

	Maturation & Optimisation of the Dynamic Dashboard
	
	o Semi-automated data integration –
	  - Creation of data transfer interfaces from selected funders – work ongoing with NIH
	o Evaluation of expansion beyond human bacterial and fungal infectious agents and inclusion of industry data
	  - Decision to be taken in consultation with Board Members and Stakeholder Group
	  - Overview of venture capital investments in SMEs - initial study started 2022 – ongoing
	o Expansion of geographical coverage of funders, including increased representation from non-high income countries
	o Ongoing updates to the Pipeline Gallery:
	  • Based on recent WHO reports – clinical data only:
	    - *2021 Antibacterial agents in clinical and preclinical development: an overview and analysis*
	    - *Bacterial vaccines in clinical and preclinical development 2021*
	  • Inclusion of access and surveillance data from *Access to Medicines Foundation* for antibacterials listed in the gallery (started August 2022)
	o Overall improvements to search and filter functions across all three galleries:
	  - Refinement of the Power BI data model to optimize data connectivity and subsequent speed of the Dashboard
	  - Search terms for human fungal priority projects to updated based on WHO Fungal Priority Pathogens List
	  - Update of search terms and tags for gender/social aspects of AMR
		Ongoing throughout 2023-2024

	Reports, Policy Briefs and Position Papers to provide an evidence base for decision making.
	
	   o **Thematic areas**:
	      - One Health;
	      - Market Incentives (includes market entry support, clinical trials, stewardship, access, regulatory issues, and financial models)
	      - Diagnostics
	   o **Reports & Policy Briefs** in thematic areas – 1-2 per year. Examples:
	      - G7 Progress Report on activities to support antibiotic development 2023 & 2024
	      - Development & Uptake of Diagnostics
	   o **Position Papers** - Hub View – Regular position papers on areas of general interest to the field - provide policy makers with the Hub view on each topic using data from Dashboard and external studies to provide basis for viewpoint – 1 per year.
	      - Reports in collaboration with expert partners
	      - Delivery of outputs at strategic time points – i.e., that pre-empt key dialogues and meetings at the highest political levels.
		Ongoing throughout 2023-2024

	External Studies Themes to be decided upon in Working Groups and Board Meetings – 1-2 external studies by end of working period (Dec 2024), depending on scope.	Ongoing throughout 2023 & 2024

Pillar 2: Enhance collaboration and coordination

Focus	Strategic collaborations – co-creating solutions
Outcome	Global and national actions on AMR R&D are guided by data and are co-ordinated
Key Performance Indicator	o Number of formal collaborations between Hub members arising from Hub interactions o Number of co-operation agreements between the Hub and external partners (based on formal agreements, joint development and/or publication of products and outputs)

Activities	Establishment and maintenance of Board Member working groups/tracks to promote co-development of solutions. o Pull Incentive track - initiated in April 2022 o One Health track - to be initiated in Q3 2023 o Hub Sustainability track - initiated in	Ongoing through 2023-2024
	Strategic collaborations; ongoing pro-active engagement with key actors in the AMR policy and R&D landscape, including the AMR and One Health global architecture. o Quadripartite, GLG on AMR, G7, and G20 • Focus on future connections to G7 Japan & Italy, G20 India & Brazil to have opportunity to shape narrative at early stage o Independent Panel on Evidence for Action Against AMR o Hub Stakeholders o International Organisations o Key AMR R&D centres (researcher perspectives on gaps In AMR R&D) - Providing evidence and data and hosting aligned events and meetings. - Ongoing facilitation of collaborations and connections.	Ongoing throughout 2023-2024

Pillar 3: Promote awareness, knowledge and visibility

Focus	Raising Awareness – pro-active not reactive	
Outcome	Elicit concrete and sustainable actions on AMR R&D at the highest political levels	
Key Performance Indicators	o Number of Hub outputs that advocate for and identify solutions/gaps/opportunities for sustainable investment in AMR R&D o Number of Hub reports/updates commissioned by or submitted to high-level political fora (e.g. G20, G7, GLG) o Number of high-level decisions related to Hub outputs and recommendations o Number of Hub-hosted high-level events o Number of references (google trends/others) to the Hub	
Activities	Increasing visibility of AMR at the highest political levels o Based on the evidence-base from the Dynamic Dashboard and external studies, advocate for increased, sustainable and focused investment in AMR R&D, and for aligned action across countries on market incentives and access o Liaise and work with strategic partners to amplify aligned messages	Ongoing throughout 2022-2024
	Communication & Dissemination Activities o Hub-hosted conferences & workshops: 　- Host Global AMR R&D Hub workshop/conference (1x per year). o Participation in external conferences and workshops. o Communication Strategy Update o Website refresh and 'brand' polish 　o Update and refresh of existing website (excludes the Dynamic Dashboard) to ensure key audience groups are targeted, Hub activities and outputs are showcased and user friendliness is enhanced o Newsletter (x4 per year) o AMR Snapshots Interview Series (x4 per year) o Peer-reviewed and media articles targeting key audiences.	Ongoing throughout 2022-2024